Environmental, Social & Governance Report – FY 2024
We believe that by advancing the health of women, we advance the health of society. Our ESG priorities are embedded throughout our business, where we focus on the issues that matter most to our stakeholders, our company, and women around the world. This is our latest FY 2024 report.
Learn more
Uninterrupt Your Contraception
In Australia, there are 16 types of contraception options available including not everyday options like long-acting reversible contraception, and everyday options like the pill or mini-pill. With 93% of women getting the contraception choice they ask for, it’s important to know what's available.
Visit the website
The Path to Parenthood
Your path to parenthood is unique, and we recognise that it comes with its own set of questions and uncertainties. That’s why we’ve created this space where you can gain insights and answers and hear from others experiences.
Visit the website
The Impact of Unintended Pregnancies in Australia
The report outlines the significant social and broader health impact of unintended pregnancy in Australia. The results highlight the need to address reproductive healthcare in Australia, to empower women to make the best health choices for their circumstances.
Read the Report
The Impact of Unintended Pregnancies in Australia by State and Territory
This report provides further detailed analysis of the financial, social and broader health impact of unintended pregnancy in Australia by state and territory including direct costs, indirect costs and the impact and the comparison of non-rural vs. rural pregnancies in each state and territory
Read the Report
Organon Women's Fertility Study
The study captures and analyses the responses from a quantitative online survey of over 2,000 women aged 18 – 45 years. The aim of this study is to understand women's perceptions and their attitudes.
Read the Report
Australian Woman and Migraine Study
For Australian women, migraine can affect every facet of their life. This study reveals the social economic and physical impact of migraine on more than 1,000 Australian women aged 21-50.
Read the Infographic
Biosimilar Policy Roadmap
This report outlines the potential of Biosimilars in Australia including an analysis of manufacturing and R&D, health technology assessment, pricing & reimbursement, contracting, education & understanding of Biosimilars, and more.
Read the Report
Environmental, Social & Governance Report – FY 2021
This FY 2021 report outlines how our ESG strategy is being implemented and embraced across the organisation globally. This report details our considerable progress in our inaugural year as a standalone company, as well as the goals we have set for the years ahead.
Read the Report